Abstracts tagged "Bisphosphonates"

Abstract Number: 350 • 2015 ACR/ARHP Annual Meeting
Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study
JungHee Koh¹, Ji Hyeon Ju², Min Kyung Chung³, Ji Hun Kim³, Seung Min Jung⁴, Ji Yeon Lee², Jennifer Lee³, Seung-Ki Kwok⁵ and Sung-Hwan Park³, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than and those without RA, and are therefore exposed to Bisphosphonates (BPs) for longer.…
Abstract Number: 355 • 2015 ACR/ARHP Annual Meeting
The Clinical and Genetic Spectrum of Low Alkaline Phosphatase in Adults
Leyre Riancho-Zarrabeitia¹, Maria T. García-Unzueta², Jair A. Tenorio³, Juan Gómez-Gerique⁴, Víctor L Ruiz Pérez³, Karen E. Heath³, Pablo Lapunzina³ and José A. Riancho⁵, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Institute of Medical and Molecular Genetics. Hospital U. La Paz. IdiPAZ. Autonomous University of Madrid. CIBERER., Madrid, Spain, ⁴Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. University of Cantabria, Santander, Spain
Background/Purpose: Different from infantile forms, adult forms of hypophosphatasia have less severe manifestations and may go unrecognized. Low serum levels of alkaline phosphatase (ALP), the…
Abstract Number: 368 • 2015 ACR/ARHP Annual Meeting
The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital
Masei Suda¹, Masato Okada¹, Yasuhiro Suyama², Mitsumasa Kishimoto¹ and Tokutaro Tsuda¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Rheumatology, JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most clinically significant side effects of glucocorticoid use, and the prevention of GIOP has become more important…
Abstract Number: 372 • 2015 ACR/ARHP Annual Meeting
Prevalence of Atypical Fractures in a Tertiary Hospital
Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, César Antonio Egües Dubuc, Carlos Francisco Meneses Villalba, Vicente Aldasoro Caceres, Joaquin Belzunegui Otano and Gaspar De la Herran, Donostia University Hospital, San Sebastian, Spain
Background/Purpose: Actually, Biphosphonates are considered the first line treatment for osteoporosis. One of the side effects of the continuous treatment with these drugs is the…
Abstract Number: 384 • 2015 ACR/ARHP Annual Meeting
Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Oral health is an important issue for the patients with rheumatoid arthritis (RA) because many RA patients were treated with bisphosphonates and bisphosphate use…
Abstract Number: 898 • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate
PD Miller¹, N Pannacciulli², JP Brown³, E Czerwinski⁴, BS Nedergaard⁵, MA Bolognese⁶, J Malouf⁷, HG Bone⁸, JY Reginster⁹, A Singer¹⁰, C Wang², RB Wagman² and SR Cummings¹¹, ¹Colorado Center for Bone Research, Lakewood, CO, ²Amgen Inc., Thousand Oaks, CA, ³Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁴Krakow Medical Center, Krakow, Poland, ⁵Center for Clinical and Basic Research, Aalborg, Denmark, ⁶The Bethesda Health Research Center, Bethesda, MD, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Michigan Bone and Mineral Clinic, Detroit, MI, ⁹University of Liège, Liège, Belgium, ¹⁰Georgetown University Medical Center, Washington, DC, ¹¹San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA
Background/Purpose: Oral bisphosphonates are the most common osteoporosis treatment, but inconvenient dosing regimens and side effects lead to low adherence. Less frequently dosed bisphosphonates, eg,…
Abstract Number: 1561 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Doo-Ho Lim¹, Seokchan Hong², Soo Min Ahn², Byeongzu Ghang³, Wook Jang Seo⁴, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Osteoporosis is more frequently observed in patients with rheumatoid arthritis (RA) than in general population. Bisphosphonate (BP), which suppresses bone resorption by inhibiting osteoclast…
Abstract Number: 1162 • 2014 ACR/ARHP Annual Meeting
Patterns of Use of Long-Term (> 5 Years) Oral Bisphophonate Prescription Among Primary Care Providers and Rheumatologists for the Treatment of Osteopenia and Osteoporosis in a Veteran Population
Mathilde Pioro¹, Stephanie Ogorzaly² and Maya Mattar³, ¹Rheumatology, Cleveland Veterans Affairs Medical Center, Cleveland, OH, ²Pharmacy Service, Veterans' Affairs Medical Center, Cleveland Veterans' Affairs Medical Center, Cleveland, OH, ³Medicine/Rheumatology, University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: Osteoporosis is a widely prevalent but underrecognized condition. Oral bisphosphonates are considered first-line treatment of osteoporosis in men and women however long term use…
Abstract Number: 854 • 2014 ACR/ARHP Annual Meeting
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial
Chi Chiu Mok¹, Angela Li², Kar Li Chan¹ and Ling Yin Ho¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Radiology, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To compare the efficacy of golimumab(GLM) and pamidronate(PAM) in the treatment of SpA.Methods Inclusion criteria: (1) patients ≥18 years of age; (2) fulfills the…
Abstract Number: 831 • 2014 ACR/ARHP Annual Meeting
Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)
Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa Blagojevic-Bucknall and Christian Mallen, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Acute pseudogout is the most dramatic clinical manifestation of calcium pyrophosphate crystal deposition (CPPD). CPPD is most commonly sporadic and age-related but can rarely…
Abstract Number: 48 • 2014 ACR/ARHP Annual Meeting
Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study
Jonathan D. Adachi¹, David Goltzman², Ankita Modi³, Jackson Tang⁴, Chun-Po S. Fan⁴ and Jessica Weaver³, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²McGill University, Montreal, QC, Canada, ³Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, ⁴Asclepius Analytics, New York, NY
Background/Purpose Individuals with osteoporosis (OP) have an increased susceptibility to fractures. Prevention and treatment of postmenopausal OP is critical to decreasing the risk of non-traumatic…
Abstract Number: 2261 • 2014 ACR/ARHP Annual Meeting
A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis
Zsolt Kulcsar¹, Lena Saleh², Shravani Gangidi³ and Poonam Khadka⁴, ¹Rheumatology/Leadership Preventive Medicine Residency, Dartmouth Hitchcock Medical Center, lebanon, NH, ²The Dartmouth Institute For Healthcare Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute For Healthcare Policy and Clinical Practice, lebanon, NH, ⁴Endocrinology, Dartmouth Hitchcock Medical Center, lebanon, NH
Background/Purpose: Bisphosphonates are currently the drug of choice for treatment of osteoporosis. While anabolic agents like parathyroid hormone (PTH) have shown greater improvements in bone…
Abstract Number: 2263 • 2014 ACR/ARHP Annual Meeting
Continued Zoledronic Acid Use in a Large Healthcare System
Robert A. Overman¹, Julie C. Lauffenburger², Margaret L. Gourlay³ and Chad L. Deal⁴, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Family Medicine, University of North Carolina, Chapel Hill, NC, ⁴Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Oral bisphosphonates adherence has been reported as less than 50% at one year. With patients frequently having refill gaps greater than 30 days. Zoledronic…
Abstract Number: 2265 • 2014 ACR/ARHP Annual Meeting
Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients
Kowoon Joo¹, Won Park², Seong-Ryul Kwon³, Mie-Jin Lim³ and Kyong-Hee Jung³, ¹Inha University Hospital, Incheon, South Korea, ²Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Background/Purpose: Rheumatoid arthritis (RA) accelerates bone loss, increasing the risk of osteoporosis and osteoporotic fractures. We evaluated the effect of raloxifene and bisphosphonate on bone…
Abstract Number: 1236 • 2013 ACR/ARHP Annual Meeting
Outcomes and Costs Of Sacral Insufficiency Fractures
Shahryar Hadavi¹, Sanam Kia¹, Christian Dejaco², Bhaskar Dasgupta² and Frances Borg³, ¹Rheumatology Department, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom
Background/Purpose: Sacral insufficiency fracture (SIF) is a poorly recognised cause of lower back pain in the elderly with significant potential morbidity. Diagnosis is often slow…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].